| REVIEW ARTICLE |
|
| Year : 2021 | Volume
: 8
| Issue : 1 | Page : 73-82 |
|
|
Novel active pharmaceutical ingredients from India: The actors-Part-I
Prasanta Kumar Ghosh
Ex-Adviser, Department of Biotechnology, Ministry of Science and Technology, Government of India and Managing Partner, Sompradip Publishers and Consultants, New Delhi, India
Correspondence Address:
Dr. Prasanta Kumar Ghosh
Ex-Adviser, Department of Biotechnology, Ministry of Science and Technology, Government of India and Managing Partner, Sompradip Publishers and Consultants, New Delhi 110058.
India
 Source of Support: None, Conflict of Interest: None  | 3 |
DOI: 10.4103/mgmj.mgmj_12_21
|
|
|
Sixteen novel active pharmaceutical ingredients, namely Urea stibamine, Methaqualone, Enfenamic acid, Hamycin, Centimizole, Centbutindole, Ormiloxifene, Centpropazine, Centbucridine, Alpha-beta-arteether, Bulaquine, Chandonium Iodide, Sintamil, Amoscanate, Saroglitizar, and Diperoxochloric Acid (DPOCL), were discovered from India. Six formulations, namely of Ormiloxifene, Alpha-beta-arteether, Bulaquine, Sintamil, Saroglitizar, and DPOCL, are in the market. The Indian pharmaceutical industry uses nearly 2200 active pharmaceutical ingredients (APIs) for the manufacture of nearly 60,000 branded generic and generic formulations from its nearly 3000 manufacturing units. The industry manufactures nearly 1000 APIs locally and imports about another 1200 APIs; the manufacture of generic APIs as well as formulations is heavily dependent on imports. To remain a dominant manufacturer, India needs to invest in the discovery of novel APIs. |
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
